Trial Profile
Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation in Patients With Multiple Sclerosis
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2017
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Therapeutic Use
- 26 Aug 2015 New trial record